This Week in Healthcare — Brussels (#28, 2026)
Digital Omnibus on AI Regulation (EU) 2026/1744 in force; changes for medical AI and MDR/IVDR; EU/Commission authorisations for hand disinfection; galacto-oligosaccharide use extended.
July 19, 2026 to July 25, 2026
Digital Omnibus on AI Regulation (EU) 2026/1744 in force; changes for medical AI and MDR/IVDR; EU/Commission authorisations for hand disinfection; galacto-oligosaccharide use extended.
📋 In This Week's Newsletter
• 🇪🇺 European Commission
• ⚖️ EU Legislation
• 📚 What We're Reading This Week
European Commission
Commission grants EU authorisation for Lyso IPA Hand Disinfection biocidal product family
On 30 June 2026, the European Commission adopted Implementing Regulation (EU) 2026/1429, published in OJ L 2026/1429, authorising 'Lyso IPA Hand Disinfection' as a biocidal product family under Regulation (EU) No 528/2012. The authorisation, granted to Schuelke & Mayr GmbH, applies Union-wide from 11 August 2026 until 30 September 2035 for product-type 1 (hygiene of human skin). The product contains propan-2-ol as its active substance, and the conditions set out in the Summary of Product Characteristics must be met. The authorisation aligns expiry with the reference product family 'desmanol pure,' previously authorised under (EU) 2025/1905. The Regulation entered into force twenty days post-publication and applies directly in all Member States.
EU Legislation (Official Journal)
Digital Omnibus on AI: Regulation (EU) 2026/1744 amends AI Act, MDR, and IVDR for harmonised implementation
Regulation (EU) 2026/1744, published on 24 July 2026 in OJ L 2026/1744, amends Regulations (EU) 2024/1689 (the AI Act), (EU) 2018/1139 (civil aviation), and (EU) 2023/1230 (machinery), with direct relevance to the healthcare sector. The Regulation clarifies the treatment of medical devices and in vitro diagnostic medical devices under MDR (Regulation (EU) 2017/745) and IVDR (Regulation (EU) 2017/746), focusing on the conformity assessment of high-risk AI systems as safety components. Notified Bodies may now follow unified assessment procedures, and the definition of 'safety component' is redefined to limit administrative burden. Entry into force is immediate, with key application dates of 2 August 2027 for certain AI systems and 2 August 2028 for MDR/IVDR-related AI, including their real-world testing and conformity assessment provisions.
Novel Food Regulation: Use conditions for galacto-oligosaccharide amended and extended
Commission Implementing Regulation (EU) 2026/1749, published in OJ L 2026/1749 on 21 July 2026, amends Regulation (EU) 2017/2470 to extend and clarify the authorised conditions of use for galacto-oligosaccharide as a novel food under Regulation (EU) 2015/2283. The amendments follow a scientific opinion by the European Food Safety Authority (EFSA Journal 2025;23:e9797) and include new food categories and maximum levels, encompassing powdered drink bases, cocoa-based drinks, and various processed foods, addressing regulatory consistency with other sectoral law for the food and nutrition industry.
What We're Reading This Week
- From housing to healthcare: What are Europeans worried about in 2026?: Survey data reveal shifting European concerns, with housing and healthcare emerging as top priorities for 2026 policy agendas.
- ‘Caporalato’, the system that enslaves thousands of migrants in Italy’s fields: ‘If you don’t do what they ask, they threaten to set you on fire’
